Synthaverse (SVE.WA) Stock Price
Synthaverse Price
Revenue has compounded at 2.2% per year over the past 16 years to 42.01 M PLN. Earnings per share have grown at 11.5% per year over the last 15 years. Synthaverse's net margin stands at -47.4%, down from 10.3% several years earlier. Analysts set a median price target of 6.63 PLN, implying 138.5% above the current price. Of 5 analysts, 4 rate the stock a buy — an overall Buy consensus.
Synthaverse stock price
Access this data via the Eulerpool API
100,000 free requests/mo · no credit card
Synthaverse business model & stock analysis
Frequently asked questions about Synthaverse
The business model of Biomed Lublin Wytwórnia Surowic i Szczepionek SA is focused on the production and distribution of vaccines, serums, and biological products. As a professional stock website, we provide information on the business strategies and operations of Biomed Lublin Wytwórnia Surowic i Szczepionek SA. This Polish company aims to cater to the healthcare industry by delivering high-quality healthcare solutions through the development and manufacturing of vaccines and serums. Biomed Lublin Wytwórnia Surowic i Szczepionek SA's business model revolves around meeting the growing demands for immunization and contributing to public health both nationally and globally.
Biomed Lublin Wytwornia Surowic i Szczepionek SA is primarily active in the pharmaceutical and biotechnology industries.
The main competitors of Biomed Lublin Wytwornia Surowic i Szczepionek SA in the market are other pharmaceutical companies operating in the vaccine and serum production industry. Some notable competitors include GlaxoSmithKline, Pfizer, Sanofi, Merck & Co., and Johnson & Johnson.
Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Polish pharmaceutical company specializing in the development and production of vaccines and serums. With a rich history spanning several decades, Biomed Lublin has emerged as a key player in the healthcare industry. Established in 1950, the company has continuously evolved, leveraging its expertise in immunology and microbiology to create innovative biopharmaceutical solutions. Over the years, Biomed Lublin has contributed significantly to public health, delivering high-quality vaccines to protect against various diseases. Their commitment to research, state-of-the-art facilities, and stringent quality controls has earned Biomed Lublin Wytwornia Surowic i Szczepionek SA a reputation for excellence in the pharmaceutical market.
Biomed Lublin Wytwornia Surowic i Szczepionek SA has achieved several significant milestones. The company has successfully developed and manufactured a range of high-quality vaccines and sera, contributing to the improvement of public health worldwide. It has obtained various regulatory approvals, ensuring the safety and efficacy of its products. Biomed Lublin has also established partnerships with reputable international organizations and pharmaceutical companies, enhancing its global presence in the biopharmaceutical industry. Additionally, the company has invested in research and development, leading to advancements in vaccine production technology and the development of new innovative products. These achievements showcase Biomed Lublin Wytwornia Surowic i Szczepionek SA's dedication to excellence and its commitment to addressing global healthcare challenges.
Biomed Lublin Wytwornia Surowic i Szczepionek SA is primarily present in Poland.
Biomed Lublin Wytwornia Surowic i Szczepionek SA is a renowned company that embodies strong values and a clear corporate philosophy. With its dedication to excellence, innovation, and customer satisfaction, Biomed Lublin strives to provide high-quality vaccines and serum products. The company emphasizes transparency, integrity, and responsible corporate citizenship in all its operations. Biomed Lublin's commitment to research and development ensures the continuous improvement of its products, enabling it to contribute significantly to the healthcare industry. By prioritizing safety, efficacy, and ethical business practices, Biomed Lublin Wytwornia Surowic i Szczepionek SA demonstrates its dedication to improving global health and saving lives.
Analysts currently set an average price target of 6.63 PLN for the Synthaverse stock (median: 6.63 PLN), implying +138.5 % versus the latest price. The consensus is based on 5 analyst ratings.
5 analysts currently rate the Synthaverse stock: 4 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Synthaverse to generate revenue of 47.00 M PLN and earnings per share of -0.40 PLN.
Converted at the current exchange rate, the Synthaverse share trades at 0.64 EUR (2.78 PLN).
The Synthaverse share (SVE.WA) is listed on 5 stock exchanges, including: London (0RKM.L), Frankfurt (6NQ.F), München (6NQ.MU).
Biomed Lublin Wytwornia Surowic i Szczepionek SA is a Polish company specializing in the production of vaccines, serum, and other biological products. The company was established in 1950 and has experienced continuous growth since then. Biomed Lublin is an important member of the Polish biotechnology industry and has established itself as a key supplier of medical products. The company focuses on the production of vaccines, including tetanus, diphtheria, scarlet fever, polio, hepatitis A and B, typhoid, and rabies. Additionally, Biomed Lublin produces serum, antitoxins, and other antibody products that are distributed worldwide. The company's blood products and plasmapheresis products department is also an integral part of its services. Biomed Lublin has multiple state-of-the-art production facilities and the necessary equipment to ensure the quality and effectiveness of its products. It is certified and complies with Good Manufacturing Practices (GMP) standards, ensuring strict quality assurance throughout all phases of product development and manufacturing. Moreover, Biomed Lublin is involved in research and development, collaborating with leading academic institutions in Poland and abroad to create the best possible scientific basis. Exporting its products to countries worldwide is one of the core businesses of Biomed Lublin, with current partner countries including Japan, China, Brazil, Russia, and India. In conclusion, Biomed Lublin is an established biotechnology company with a long history and expertise in the production and distribution of biological products. It has a strong international network and is capable of offering high-quality products at competitive prices.
The expected revenue of Synthaverse is 47.00 M PLN. This figure is based on current financial data and reflects the company's business performance.
The expected profit of Synthaverse is -30.31 M PLN. The net profit reflects the company's profitability after deducting all expenses.
The price-to-earnings ratio (P/E) of Synthaverse is currently -6.95. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Synthaverse stock.
The price-to-sales ratio (P/S) of Synthaverse is currently 4.48. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Synthaverse stock.
The Eulerpool Quality Score for Synthaverse is 1/10.
The ISIN of Synthaverse is PLBMDLB00018. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.
The WKN of Synthaverse is A1J10U. The WKN (Wertpapierkennnummer) is a six-digit German security identification number.
The ticker of Synthaverse is SVE.WA. The ticker symbol is used to trade Synthaverse shares on the stock exchange.
Synthaverse stock
Synthaverse Peer Group
Synthaverse Ticker
Synthaverse FIGI
All fundamentals and in-depth analysis of Synthaverse
Our stock analysis for Synthaverse stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Synthaverse. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.